Clinical and etiologic characteristics of de novo uveitis in patients aged 60 years and above: experience of a French tertiary center.


Journal

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 01 04 2019
accepted: 02 07 2019
revised: 05 06 2019
pubmed: 18 7 2019
medline: 27 8 2019
entrez: 18 7 2019
Statut: ppublish

Résumé

To describe the characteristics of de novo uveitis in patients ≥ 60 years old. Retrospective review of patients with uveitis followed in our tertiary center over a 14-year period. Patients aged 60-70 years and patients aged > 70 years were compared. A total of 283/1044 (27.1%) patients with uveitis were ≥ 60 years of age. Idiopathic uveitis (36.1%) and sarcoidosis (31.5%) were the most frequent etiologies. Sarcoidosis was significantly more frequent (31.5% vs. 13.7%, p < 0.0001) after the age of 60 years. Intraocular lymphoma (5.0% vs. 1.1%) and herpes virus infection (5.0% vs. 0.9%) were also more common in this age group, unlike HLA B27-related uveitis and spondyloarthritis (4.6% vs. 14.9%). Pure ophthalmologic entities: birdshot retinochoroidopathy (2.8%) or Fuchs uveitis (0.4%), were rare in patients ≥ 60 years of age and Posner Scholssman, Pars planitis, White dots syndrome, Behçet's disease, and Multiple Sclerosis were never reported. In patients > 70 years old, idiopathic uveitis (41.1% vs. 31.7%) and presumed sarcoidosis (56.5% vs. 25.6%) were more frequent than in the 60-70-year age group. In our center, sarcoidosis is the leading cause of non-idiopathic uveitis in older patients. Idiopathic uveitis and other entities account for less than two-thirds of cases. Ophthalmologic entities are rare after 60 years of age. We also report for the first time the characteristics of uveitis after 70 years of age.

Identifiants

pubmed: 31312906
doi: 10.1007/s00417-019-04411-1
pii: 10.1007/s00417-019-04411-1
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1971-1979

Références

Rev Med Interne. 2000 Dec;21(12):1131-2
pubmed: 11191683
Am J Ophthalmol. 2001 May;131(5):647-52
pubmed: 11336942
J Fr Ophtalmol. 2003 Sep;26(7):720-4
pubmed: 13130260
Br J Ophthalmol. 1964 Sep;48:461-70
pubmed: 14217212
Rev Med Interne. 2003 Dec;24(12):794-802
pubmed: 14656639
Ophthalmology. 2004 Mar;111(3):491-500; discussion 500
pubmed: 15019324
Arthritis Rheum. 2004 Dec 15;51(6):974-82
pubmed: 15593175
Am J Ophthalmol. 2006 Jan;141(1):185-7
pubmed: 16386995
Surv Ophthalmol. 2007 Nov-Dec;52(6):561-87
pubmed: 18029267
J Chin Med Assoc. 2007 Nov;70(11):492-6
pubmed: 18063503
Ann Rheum Dis. 2009 Jun;68(6):777-83
pubmed: 19297344
Arthritis Rheum. 1991 Oct;34(10):1218-27
pubmed: 1930310
Ocul Immunol Inflamm. 2009 May-Jun;17(3):179-84
pubmed: 19585360
Lancet. 1990 May 5;335(8697):1078-80
pubmed: 1970380
Ann Rheum Dis. 2011 Jan;70(1):25-31
pubmed: 21109520
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Ocul Immunol Inflamm. 2011 Aug;19(4):219-26
pubmed: 21770796
PLoS One. 2013;8(2):e52385
pubmed: 23405064
J Ophthalmic Inflamm Infect. 2013 Jan 03;3(1):2
pubmed: 23514612
Doc Ophthalmol. 1989 Aug;72(3-4):287-96
pubmed: 2625091
Int J STD AIDS. 2017 Oct;28(12):1224-1228
pubmed: 28201950
Am J Ophthalmol. 2017 Jun;178:176-185
pubmed: 28366648
Br J Ophthalmol. 2018 Jan;102(1):79-83
pubmed: 28596287
Ophthalmology. 2018 Jan;125(1):119-126
pubmed: 28823384
Autoimmun Rev. 2017 Dec;16(12):1254-1264
pubmed: 29037906
Am J Ophthalmol. 1987 Feb 15;103(2):234-5
pubmed: 3812627
Ann Ophthalmol. 1982 Oct;14(10):942-4
pubmed: 6891197
Eye (Lond). 1994;8 ( Pt 3):288-91
pubmed: 7958032
Klin Monbl Augenheilkd. 1994 May;204(5):319-22
pubmed: 8051862
Ophthalmology. 1998 Feb;105(2):347-52
pubmed: 9479298

Auteurs

P Grumet (P)

Servicede Médecine Interne, Hôpital de la Croix-Rousse, Hospic es Civils de Lyon, Université Claude Bernard-Lyon 1, 103 grande rue de la Croix-Rousse, 69318, Lyon Cedex 04, France.

S Kerever (S)

Service d'Anesthésie-Réanimation, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France.

T Gilbert (T)

Service de Gériatrie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université Claude Bernard-Lyon 1, Lyon, France.

L Kodjikian (L)

Service d'Ophtalmologie, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Université Claude Bernard-Lyon 1, Lyon, France.

M Gerfaud-Valentin (M)

Servicede Médecine Interne, Hôpital de la Croix-Rousse, Hospic es Civils de Lyon, Université Claude Bernard-Lyon 1, 103 grande rue de la Croix-Rousse, 69318, Lyon Cedex 04, France.

A De Parisot (A)

Servicede Médecine Interne, Hôpital de la Croix-Rousse, Hospic es Civils de Lyon, Université Claude Bernard-Lyon 1, 103 grande rue de la Croix-Rousse, 69318, Lyon Cedex 04, France.

Y Jamilloux (Y)

Servicede Médecine Interne, Hôpital de la Croix-Rousse, Hospic es Civils de Lyon, Université Claude Bernard-Lyon 1, 103 grande rue de la Croix-Rousse, 69318, Lyon Cedex 04, France.

P Sève (P)

Servicede Médecine Interne, Hôpital de la Croix-Rousse, Hospic es Civils de Lyon, Université Claude Bernard-Lyon 1, 103 grande rue de la Croix-Rousse, 69318, Lyon Cedex 04, France. pascal.seve@chu-lyon.fr.
Hospices Civils de Lyon, Pôle IMER, F-69003, Lyon, France. pascal.seve@chu-lyon.fr.
Univ. Lyon, University Claude Bernard Lyon 1, HESPER EA 7425, F-69008, Lyon, France. pascal.seve@chu-lyon.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH